Stanford University’s loss, regenerative medicine’s gain - and the world will also enjoy significant gains in healthcare when Divya Nag completes her new technology, known as the induced pluripotent stem cell. Divya has no regrets about her decision to drop out of Stanford so that she can become the co-founder of Stem Cell Theranostics and StartX Med. She was passionate about the technology, which made it very clear what she wanted to do with her life.
Divya is tackling of the most challenging issues in modern medicine, namely, that most types of human cells will die in a petri dish. Testing new drugs before approval for market release becomes a costly, risky and time-consuming activity that result in losses to both the pharmaceutical company and the consumers. Emphasis must be made that 90% of new drugs on clinical trials will eventually prove to be unsafe or ineffective for the consumer market.
With Divya’s induced pluripotent stem cell technology, there is hope in the horizon. The technology turns cells into embryonic-like stem cells that can then be used to create a wide range of cells, such as heart cells. These cells have the ability to live in perti dishes, thus, enabling researchers to test new drugs at lesser risks, costs and time investments.
No comments:
Post a Comment